Additionally, PDGFR is involved in regulating interstitial fluid pressure, and imatinib can inhibit this signaling in the tumor microenvironment, leading to a reduction in interstitial fluid pressure and potentially enhancing drug delivery to the tumor tissues [35]. This evidence concerns the gene PDGFRB and neoplasm.